On catatonia again... - literature review
DOI:
https://doi.org/10.12775/JEHS.2023.24.01.005Keywords
catatonia, treatmen, drugs, immunologyAbstract
Introduction: In addition to the symptoms, the symptoms of catatonia have been classified as a subtype of schizophrenia (catatonic schizophrenia). Currently, however, catatonia is treated as a single psychopathological syndrome that can occur in the course of various disorders. Catatonia has been the subject of many disputes in the scientific community over the years, and many of its elements remain unexplored.
Material and method: The aim of the study is to review current research on catatonia in the field of: main, leading to catatonia, neuroimaging, immunology, methods of treatment and psychoactive compounds, COVID-19, therapy of pediatric and geriatric patients. The article reviews research and scientific papers from 2014-2022 on catatonia, interest in the PubMed and Google Scholar databases.
Results: Studies showing a prevalence of catatonia of approximately 10.6 cases per 100,000 tax recipients. The assessment of the prevalence of individual catatonias varies depending on the criteria. Deep vein embolism has been confirmed in approximately 25.3% of patients with cardiac catatonia.
Conclusions: Catatonia is a common neuropsychiatric syndrome that significantly prolongs hospitalization time. Additional studies using the technique of functional neuroimaging of the brain are needed. Effects of treatment with the effect of: zolpidem, memantine, amantadine and augmentation with amisulpiride.
References
Fink M. Rediscovering catatonia: the biography of a treatable syndrome. Acta Psychiatr Scand Suppl 2013:1–47.
Jarema M, Barbaro B, Wydawnictwo Lekarskie PZWL. Psychiatria: podrecznik dla studentów medycyny. Warszawa: Wydawnictwo Lekarskie PZWL; 2016.
Tandon R, Heckers S, Bustillo J, Barch DM, Gaebel W, Gur RE, et al. Catatonia in DSM-5. Schizophr Res 2013;150:26–30.
Chakrabarti S. Psychotic and catatonic presentations in bipolar and depressive disorders. World Psychiatry 2012; 11 (Suppl 1): 59-64.
Reed GM, First MB, Kogan CS, Hyman SE, Gureje O, Gaebel W, et al. Innovations and changes in the ICD‐11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry 2019;18:3–19.
Krawczyk P, Święcicki Ł. ICD-11 vs. ICD-10 – a review of updates and novelties introduced in the latest version of the WHO International Classification of Diseases. Psychiatr Pol 2020;54:7–20.
Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand 1996;93:129–136.
https://www.mdcalc.com/calc/10239/bush-francis-catatonia-rating-scale
Rogers JP, Pollak TA, Begum N, Griffin A, Carter B, Pritchard M, et al. Catatonia: demographic, clinical and laboratory associations. Psychol Med 2021:1–11.
Subramaniyam BA, Muliyala KP, Hari Hara S, Kumar Reddi VS. Prevalence of catatonic signs and symptoms in an acute psychiatric unit from a tertiary psychiatric center in India. Asian Journal of Psychiatry 2019;44:13–7.
Ameele S, Sabbe B, Morrens M. Characteristics of catatonia in schizophrenia and mood disorders. Tijdschrift Voor Psychiatrie 2015;57:94–8.
Cuevas-Esteban J, Iglesias-González M, Rubio-Valera M, Serra-Mestres J, Serrano-Blanco A, Baladon L. Prevalence and characteristics of catatonia on admission to an acute geriatric psychiatry ward. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2017;78:27–33.
Pelzer A, van der Heijden F, den Boer E. Systematic review of catatonia treatment. NDT 2018;Volume 14:317–326.
Yamamura S, Ohoyama K, Hamaguchi T, Kashimoto K, Nakagawa M, Kanehara S, et al. Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. Psychopharmacology 2009;206:243–58.
Unal A, Bulbul F, Alpak G, Virit O, Copoglu US, Savas HA. Effective treatment of catatonia by combination of benzodiazepine and electroconvulsive therapy. J ECT 2013;29:206–209.
Haroche A, Rogers J, Plaze M, Gaillard R, Williams SC, Thomas P, et al. Brain imaging in catatonia: systematic review and directions for future research. Psychol Med 2020;50:1585–1597.
Sambataro F, Hirjak D, Fritze S, Kubera KM, Northoff G, Calhoun VD, et al. Intrinsic neural network dynamics in catatonia. Hum Brain Mapp 2021;42:6087–98.
Fink M, Shorter E. Does persisting fear sustain catatonia? Acta Psychiatr Scand 2017;136:441–4.
Rasmussen SA, Mazurek MF, Rosebush PI. Catatonia: Our current understanding of its diagnosis, treatment and pathophysiology. WJP 2016;6:391.
Prajapati PR, Fabius D, Pradhan B. Clinical Course and Management of Drug-Induced Catatonia and Paranoid Behavior in an Adolescent. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2016;26:310–315.
Lloyd JR, Silverman ER, Kugler JL, Cooper JJ. Electroconvulsive Therapy for Patients with Catatonia: Current Perspectives. NDT 2020;Volume 16:2191–208.
Edinoff AN, Kaufman SE, Hollier JW, Virgen CG, Karam CA, Malone GW, et al. Catatonia: Clinical Overview of the Diagnosis, Treatment, and Clinical Challenges. Neurology International 2021;13:570–586.
Selch S, Strobel A, Haderlein J, Meyer J, Jacob CP, Schmitt A, et al. MLC1 polymorphisms are specifically associated with periodic catatonia, a subgroup of chronic schizophrenia. Biol Psychiatry 2007;61:1211–1214.
Peralta V, Fañanás L, Martín-Reyes M, Cuesta MJ. Dissecting the catatonia phenotype in psychotic and mood disorders on the basis of familial-genetic factors. Schizophr Res 2018;200:20–25.
Rogers JP, Pollak TA, Blackman G, David AS. Catatonia and the immune system: a review. The Lancet Psychiatry 2019;6:620–630.
Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: The subcortical source of inflammatory malaise. Frontiers in Neuroendocrinology 2012;33:315–327.
Rossi S, Muzio L, De Chiara V, Grasselli G, Musella A, Musumeci G, et al. Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain, Behavior, and Immunity 2011;25:947–56.
Dalmau J, Geis C, Graus F. Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev 2017;97:839–87.
Espinola‐Nadurille M, Flores‐Rivera J, Rivas‐Alonso V, Vargas‐Cañas S, Fricchione GL, Bayliss L, et al. Catatonia in patients with anti‐NMDA receptor encephalitis. Psychiatry Clin Neurosci 2019;73:574–80.
Haouzir S, Lemoine X, Desbordes M, Follet M, Meunier C, Baarir Z, et al. The role of coagulation marker fibrin D-dimer in early diagnosis of catatonia. Psychiatry Res 2009;168:78–85.
Anvekar P, Lohana P, Mukhtadir Kalaiger A, Rashid Ali S, Arti A. COVID-19 INDUCED CATATONIA: A REVIEW OF THIS RARE PHENOMENON. J Ayub Med Coll Abbottabad 2022;34.
Zain SM, Muthukanagaraj P, Rahman N. Excited Catatonia - A Delayed Neuropsychiatric Complication of COVID-19 Infection. Cureus 2021;13:e13891.
Dawood AS, Dawood A, Dawood S. Catatonia after COVID-19 infection: scoping review. BJPsych Bull 2022:1–12.
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci 2020;11:995–8.
Ng QX, Yeo WS, Lim DY, Chee KT. Re-examining the Association Between COVID-19 and Psychosis. Psychosomatics 2020;61:853–5.
Vasilevska V, Guest PC, Bernstein H-G, Schroeter ML, Geis C, Steiner J. Molecular mimicry of NMDA receptors may contribute to neuropsychiatric symptoms in severe COVID-19 cases. J Neuroinflammation 2021;18:245.
Yeoh SY, Roberts E, Scott F, Nicholson TR, David AS, Rogers JP. Catatonic Episodes Related to Substance Use: A Cross-Sectional Study Using Electronic Healthcare Records. J Dual Diagn 2022;18:52–8.
Randall K, Hayward K. Emergent Medical Illnesses Related to Cannabis Use. Mo Med. 2019;116(3):226-228.
Palma-Álvarez RF, Soriano-Dia A, Ros-Cucurull E, Daigre C, Serrano-Pérez P, Ortega-Hernández G, et al. Catatonia Related to Cannabis and Synthetic Cannabinoids: A Review. Journal of Dual Diagnosis 2021;17:159–71.
Mekala H, Malik Z, Lone J, Shah K, Ishaq M. Cannabis-Induced Catatonia: A Case Series. Cureus. 2020;12(6):e8603
North N, Bishop J, Bruce D, Boardman T. Traumatic Hand Amputation Resulting in Catatonia. Air Medical Journal 2021;40:278–9.
Moskowitz AK. “Scared stiff”: catatonia as an evolutionary-based fear response. Psychol Rev 2004;111:984–1002.
Tatreau JR, Laughon SL, Kozlowski T. Catatonia After Liver Transplantation. Ann Transplant 2018;23:608–14.
Frederick RT. Extent of reversibility of hepatic encephalopathy following liver transplantation. Clin Liver Dis 2012;16:147–58.
Jones EA. Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy. Metab Brain Dis 2002;17:275–81.
Maner BS, Singh J, Camacho H, Jenson AK. Catatonia-Induced Saddle Pulmonary Embolism. Cureus 2021.
Lahutte B, Cornic F, Bonnot O, Consoli A, An-Gourfinkel I, Amoura Z, et al. Multidisciplinary approach of organic catatonia in children and adolescents may improve treatment decision making. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1393–8.
Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti–N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis in Children and Adolescents. Ann Neurol 2009;66:11–8.
Vaquerizo-Serrano J, Salazar De Pablo G, Singh J, Santosh P. Catatonia in autism spectrum disorders: A systematic review and meta-analysis. Eur Psychiatr 2022;65:e4.
Wachtel LE. Treatment of catatonia in autism spectrum disorders. Acta Psychiatr Scand 2019;139:46–55.
Hauptman AJ, Benjamin S. The Differential Diagnosis and Treatment of Catatonia in Children and Adolescents. Harv Rev Psychiatry 2016;24:379–95.
Raffin M, Zugaj-Bensaou L, Bodeau N, Milhiet V, Laurent C, Cohen D, et al. Treatment use in a prospective naturalistic cohort of children and adolescents with catatonia. Eur Child Adolesc Psychiatry 2015;24:441–9.
Catatonia: From psychopathology to neurobiology. Arlington, VA, US: American Psychiatric Publishing, Inc.; 2004.
Takács R, Asztalos M, Ungvari GS, Gazdag G. Catatonia in an inpatient gerontopsychiatric population. Psychiatry Research 2017;255:215–8.
Jaimes-Albornoz W, Ruiz de Pellon-Santamaria A, Nizama-Vía A, Isetta M, Albajar I, Serra-Mestres J. Catatonia in older adults: A systematic review. WJP 2022;12:348–67.
Swartz C, Galang RL. Adverse outcome with delay in identification of catatonia in elderly patients. Am J Geriatr Psychiatry 2001;9:78–80.
Jaimes-Albornoz W, Serra-Mestres J. Prevalence and clinical correlations of catatonia in older adults referred to a liaison psychiatry service in a general hospital. Gen Hosp Psychiatry 2013;35:512–6.
Carroll BT. Complications of catatonia. J Clin Psychiatry 1996;57:95.
Patel RS, Veluri N, Verma G. Mirtazapine Creating “Miracles” in Psychotic Depression With Catatonia. Cureus 2020;12(8):e9863.
Northoff G, Wenke J, Demisch L, Eckert J, Gille B, Pflug B. Catatonia: short-term response to lorazepam and dopaminergic metabolism. Psychopharmacology (Berl) 1995;122:182–6.
Yassa R, Iskandar H, Lalinec M, Cleto L. Lorazepam as an adjunct in the treatment of catatonic states: an open clinical trial. J Clin Psychopharmacol 1990;10:66–8.
England ML, Ongür D, Konopaske GT, Karmacharya R. Catatonia in psychotic patients: clinical features and treatment response. J Neuropsychiatry Clin Neurosci 2011;23:223–6.
Ungvari GS, Chiu HF, Chow LY, Lau BS, Tang WK. Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology (Berl) 1999;142:393–8.
Porter RJ, Baune BT, Morris G, Hamilton A, Bassett D, Boyce P, et al. Cognitive side-effects of electroconvulsive therapy: what are they, how to monitor them and what to tell patients. BJPsych Open 2020;6:e40.
Dutt A, Grover S, Chakrabarti S, Avasthi A, Kumar S. Phenomenology and treatment of Catatonia: A descriptive study from north India. Indian J Psychiatry 2011;53:36–40.
van Waarde JA, Tuerlings JHAM, Verwey B, van der Mast RC. Electroconvulsive therapy for catatonia: treatment characteristics and outcomes in 27 patients. J ECT 2010;26:248–52.
Stöber G, Saar K, Rüschendorf F, Meyer J, Nürnberg G, Jatzke S, et al. Splitting Schizophrenia: Periodic Catatonia–Susceptibility Locus on Chromosome 15q15. Am J Hum Genet 2000;67:1201–7.
Hatta K, Miyakawa K, Ota T, Usui C, Nakamura H, Arai H. Maximal response to electroconvulsive therapy for the treatment of catatonic symptoms. J ECT 2007;23:233–5.
Graziane J, Davidowicz E, Francis A. Can Memantine Improve Catatonia and Co-occurring Cognitive Dysfunction? A Case Report and Brief Literature Review. Psychosomatics 2020;61:759–63.
Chaffkin J, Josephs IA, Katz ER. Safe Use of Memantine in a Pediatric Patient With Catatonia. J Am Acad Child Adolesc Psychiatry 2022:S0890-8567(22)00292-1.
Kumar P, Kumar D. Zolpidem in treatment resistant adolescent catatonia: a case series. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology 2020;8:135–8.
Sanna E, Busonero F, Talani G, Carta M, Massa F, Peis M, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 2002;451:103–10.
Iserson KV, Durga D. Catatonia-Like Syndrome Treated With Low-Dose Ketamine. The Journal of Emergency Medicine 2020;58:771–4.
Konstantinou G, Papageorgiou CC, Angelopoulos E. Periodic Catatonia: Long-term Treatment With Lamotrigine: A Case Report. J Psychiatr Pract 2021;27:322–5.
Chen R-A, Huang T-L. Periodic catatonia with long-term treatment: a case report. BMC Psychiatry 2017;17:337.
Arora M, Banal R, Praharaj SK, Mahajan V. Amisulpride Augmentation in Acute Catatonia. American Journal of Therapeutics 2017;24:e381–5.
Ellul P, Rotgé JY, Choucha W. Resistant Catatonia in a High-Functioning Autism Spectrum Disorder Patient Successfully Treated with Amantadine. Journal of Child and Adolescent Psychopharmacology 2015;25:726–726.
Ene-Stroescu V, Nguyen T, Waiblinger BE. Excellent Response to Amantadine in a Patient With Bipolar Disorder and Catatonia. JNP 2014;26:E43–E43.
Gałecki P, Szulc A. Psychiatria. Wrocław: Edra Urban & Partner; 2018.
Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych.
Wydanie 3. Gdańsk: Via Medica, 2022.
Solmi M, Pigato GG, Roiter B, Guaglianone A, Martini L, Fornaro M, et al. Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis. Schizophrenia Bulletin 2018;44:1133–50.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Gracjan Rudzinski, Kinga Brzuszkiewicz, Kinga Pożarowska, Natalia Kusak, Borys Łozowski, Elżbieta Szczepaniak-Wójtowicz, Ewelina Soroka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 653
Number of citations: 0
